South Korea-based regenerative medicine company PharmaResearch Co., Ltd. (KOSDAQ: 214450), which develops medicines, medical devices, cosmetics and health supplements, said on Wednesday it has agreed to acquire US cosmetics manufacturer Cosmetic Group USA to strengthen its localisation strategy in North America.
PharmaResearch signed the agreement on 30 June as demand for its REJURAN Cosmetics brand increases in the United States following launches across Sephora and Amazon. Financial terms were not disclosed.
CG USA, based in California, provides OEM and ODM services covering product planning, formula development, manufacturing, filling, packaging and quality control. It operates an FDA-registered facility with a quality management system aligned with cGMP standards and has the capability to produce over-the-counter products.
PharmaResearch said the acquisition will secure a local production base, improving supply chain efficiency and responsiveness across manufacturing, logistics and distribution. The company, which currently supplies the US market with products made in Korea, aims to enhance supply stability in North America and accelerate its localisation strategy across the wider Americas. The brand is expanding through online and offline channels and is scheduled to enter Canada in the second half of the year.
Abbott and NACHC launch nationwide Food for Health initiative
Galmed reports positive preclinical results for Aramchol in prostate cancer
Galderma receives EU approval for Restylane Shaype facial shaping injectable
Sisram Medical introduces Titanium Prime treatment concept in Hong Kong SAR
Proteotype unveils Alchemi platform for blood-based multi-cancer test Enlighten
Insulet expands European footprint with Omnipod 5 and Omnipod Discover launch in Spain
Frontier IP portfolio company InSignals wins EU grant and launches Parkinson's app
PharmaResearch to acquire CG USA to support North American expansion of REJURAN Cosmetics
United Therapeutics wins FDA approval for LungFX ex vivo lung perfusion device